Impact of 13valent vaccine for prevention of pneumococcal diseases in children and adults at risk: possible sceneries in Campania region.
Pneumonias are the most frequent infectious disease, characterized by a high prevalence especially among children and adults at risk. The socio-economic impact caused by Streptococcus pneumoniae is evaluated in terms of morbidity, death rate and hospitalizations. The aim of the study was to demonstrate the potential economic advantages by implementation of an active anti-pneumococcal 13-valent vaccine strategy in Campania region ( Southern Italy) in two different categories of subjects, children (aged 0-12), and adults (aged 50-79) at risk (hypertension, nephropathies, COPD and heart diseases) Methods. Vaccination costs were compared with costs necessary to treat avoidable diseases in presence and absence of a vaccination program. Offering anti-pneumococcal 13-valent vaccine to the paediatric population was quantified as saving one million euros for Italian national health service in two years. In addition , offering anti-pneumococcal vaccine to adults at risk would generate a return of around 29 million euros. In both cases, offering anti-pneumococcal 13-valent vaccine was proven to be a helpful political health strategy, not only in consideration of a reduction of cases, but also in view of the favourable economic impacts.